Ginkgo Biloba for Circulation and Brain Blood Flow

Ginkgo biloba is one of the oldest surviving tree species on Earth, and its leaf extract is one of the most widely sold herbal supplements globally. Beyond its popular reputation as a memory supplement, ginkgo has a substantial evidence base for circulation — specifically for peripheral artery disease (claudication), cerebral blood flow, and platelet function. Understanding what the research actually shows — and where genuine evidence ends and marketing begins — is essential for informed use.

Active Compounds: Terpene Lactones and Flavonoids

Ginkgo leaf extract contains two pharmacologically active classes of compounds. Flavone glycosides (primarily quercetin and kaempferol derivatives) provide antioxidant activity and support capillary integrity. Terpene lactones — specifically ginkgolides A, B, and C, and bilobalide — are unique to ginkgo and have the most pharmacologically specific activities.

Ginkgolide B is a potent, selective antagonist of platelet-activating factor (PAF) — a lipid mediator that promotes platelet aggregation, vasoconstriction, and inflammation. PAF plays a significant role in the microcirculatory changes associated with peripheral artery disease and cerebrovascular insufficiency. By blocking PAF, ginkgo reduces platelet aggregation, improves red blood cell deformability, and promotes vasodilation — directly addressing key mechanisms of impaired circulation.

Claudication: The Strongest Circulation Evidence

Intermittent claudication — leg pain with walking caused by PAD — has the most clinical trial data for ginkgo of any circulation indication. A Cochrane systematic review of 11 RCTs found that ginkgo extract significantly improved pain-free walking distance compared to placebo, with an absolute improvement of about 34 meters. A meta-analysis of 8 trials found comparable effects.

While effect sizes are modest (smaller than supervised exercise therapy), they are clinically meaningful for patients unable to exercise effectively due to severe symptoms. Ginkgo was compared to pentoxifylline (a prescription rheologic agent) in head-to-head trials and performed similarly, supporting its pharmacological relevance rather than mere placebo effect.

Cerebral Blood Flow and Vascular Dementia

Ginkgo's effects on cerebral circulation — through improved blood rheology, platelet function, and vasodilation — have been studied in vascular dementia and cerebrovascular insufficiency. Trials using EGb 761 (the standardized extract used in most European research) show improvements in cognitive symptoms, quality of life, and neuropsychological test scores in patients with mild-to-moderate dementia.

The GEDIMED and GIM trials found significant benefits of EGb 761 (240 mg/day) on cognitive function in Alzheimer's and vascular dementia. The GRACE trial and French IADL study showed mixed results, reflecting the heterogeneity of dementia populations. The cardiovascular-cognitive connection is real — improved cerebral perfusion benefits cognition in people whose cognitive decline is partly vascular in origin.

The EGb 761 Standard

Most positive clinical trials use EGb 761 — a standardized ginkgo extract produced to contain 24% ginkgo flavone glycosides and 6% terpene lactones. This standardization is critical because ginkgo products vary enormously in active compound content. An analysis of commercial ginkgo supplements found that many did not meet EGb 761 specifications.

The dose used in most effective trials is 120-240 mg/day of EGb 761, typically divided into two doses. For cognitive and circulation applications, 120 mg twice daily is a standard evidence-based approach. Generic ginkgo products should specify their standardization to 24%/6% on the label to have confidence in comparability to trial results.

The GEMS Trial: Important Negative Finding

It is essential to discuss the Ginkgo Evaluation of Memory (GEM) study — a large, well-designed RCT of 3,069 elderly adults randomized to EGb 761 (120 mg twice daily) or placebo for 6.1 years. It found no significant reduction in the incidence of dementia or Alzheimer's disease. This does not negate ginkgo's effects on circulation and existing symptoms, but it means ginkgo cannot be recommended as a prevention strategy for dementia in cognitively healthy adults.

Safety and Drug Interactions

Ginkgo's PAF inhibition and platelet effects create significant interaction potential with anticoagulant drugs (warfarin, DOACs) and antiplatelet agents (aspirin, clopidogrel). Multiple case reports link ginkgo use with spontaneous bleeding events, including intracranial hemorrhage and subarachnoid hemorrhage. Anyone on blood thinners should discuss ginkgo with their physician before use.

FAQ

Q: Does ginkgo actually work for memory in healthy people?

Evidence in cognitively healthy individuals is weak and inconsistent. The benefit appears more consistent in people with existing cerebrovascular insufficiency or mild cognitive impairment.

Q: What is the best dose of ginkgo for circulation?

120 mg twice daily of a standardized EGb 761 extract (24% flavone glycosides, 6% terpene lactones) is the dose used in most positive clinical trials for both claudication and cognitive applications.

Q: How long does ginkgo take to improve circulation?

Claudication trials typically measure outcomes at 6-24 weeks. Subjective improvements in cold extremities and walking tolerance may be noticed within 4-8 weeks.

Q: Can ginkgo be taken with fish oil?

Both have antiplatelet properties. The combination at standard doses is likely safe for most people, but individuals on prescription anticoagulants should avoid this combination without medical supervision.

Track your supplements in Optimize.